Going Beyond the Sequence...

Precision epigenomic medicine

Founded out of the Stanford laboratory of Steve Quake, Bluestar Genomics is an early cancer detection company focused on the development and commercialization of non-invasive epigenomic tests to detect cancer through a standard blood draw, earlier than existing methods and when the disease is still treatable.

epigenomics approach to 
analyzing active biology


reinventing liquid biopsy 
through epigenomics

Non-invasive “liquid biopsy,” using cell-free DNA and high throughput genetic analyses, traditionally focuses on detecting sequence differences. This has limited big data applications to clinical conditions where such differences exist.

With the addition of epigenomics, we escape the limitations of sequence alone, providing new disease and clinical information to solve broader healthcare needs.

The company uses its one-of-a-kind epigenomic platform that combines best-in-class bioinformatics and biomedical technologies to analyze individuals’ changing biology that is yet to produce symptoms.

Song et al, Cell Research 2017


Song et al, PNAS 2016


bioRxiv Preprint, 2018


medRxiv Preprint, 2020


Bluestar Genomics presents new data showing its liquid biopsy test detects pancreatic cancer signal >> Read Press Release

Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA >> Download PDF

Bluestar Genomics Closes $70M Series C Funding, Expands Scientific Advisory Board >> Read Press Release

Bluestar Genomics Receives FDA Breakthrough Device Designation for First-of-Its-Kind Pancreatic Cancer Screening Test >> Read Press Release

In the first steps toward innovative liquid biopsy applications, Bluestar Genomics reports epigenomics results stratifying pancreatic cancer patients from cell free DNA samples. >> Read Press Release

Stanford Spinout Bluestar Genomics Develops Epigenomic Method to Detect Pancreatic Cancer. >> Read GenomeWeb Article

Aiming to improve early diagnosis of cancer using noninvasive methods, Bluestar Genomics presents data demonstrating the feasibility of a novel blood test for earlier detection and classification of multiple cancers. >> Read Press Release

Bluestar Genomics shares new noninvasive data for earlier cancer detection with promising performance at 11th CNAPs International Symposium. >> Read Press Release

Bluestar Genomics’ Breakthrough Study Highlights Promising Data for Multi-Cancer Detection from a Single Blood Draw. >> Read Press Release

Cell/Tissue Specificity

Identify changes in specific organs using a systemic sample

Biological Activity

Detect biological activity and gene expression

Disease Biomarkers

Reveal the presence and progression of disease

Drug Development

Improve therapy selection, efficacy and safety monitoring

Health Monitoring

Assess individual organ systems and biological functions

Non-Invasive Sampling

Avoid biopsy, surgery or direct tissue requirements

Systems Biology

Uncover the hidden interactions of multiple systems simultaneously


Read Bio

Samuel Levy PhD

Chief Executive Officer and Chief Scientific Officer

  • 20+ years scientific leadership in genomics and molecular diagnostic development
  • Celera, J. Craig Venter Institute, Scripps Translational Science, Genomic Health, Quanticel Pharmaceuticals (Celgene), Impact Genomics (Lexent Bio)
  • Past faculty: Scripps Translational Science Institute, Scripps Research Institute
  • University of Bristol, University of Leeds
  • “Translating complex biology and technology into valuable patient-centric products is what excites me most.”

Read Bio

Kelly Bethel MD

Chief Medical Officer

  • 20+ years experience as a practicing pathologist, specializing in diagnosis of blood cancers
  • Senior Clinical Investigator U54 NIH grant researching circulating tumor cells in patients with cancer
  • Inventor, cofounder, initial laboratory director Epic Sciences, Inc.; led CLIA/CAP certification for assay using circulating tumor cells
  • Yale University, George Washington University School of Medicine
  • “I am inspired to apply advances in technology toward the development of tests that find cancer more effectively and enable treatment to save lives.”

Read Bio

Wayne Volkmuth, PhD

Senior Vice President, Informatics and Data Discovery

  • 20+ years experience in bioinformatics, genomics and drug discovery
  • Atreca (co-founder), Innectus (co-founder), Renovis (Evotec), Ceres, Incyte Pharmaceuticals
  • 18 issued US patents
  • Stanford University; Princeton University; University of Minnesota
  • “I am privileged to help the Bluestar Genomics team develop breakthrough technologies to improve patient care.”

Read Bio

Jim Vaughn, R. Ph

Chief Commercial Officer

  • More than 20 years of experience in the global commercialization of molecular diagnostics in oncology
  • Breadth of expertise in sales, marketing, and reimbursement strategy
  • Executive commercial leadership highlights include the successful commercialization of the Oncotype DX portfolio at Genomic Health/ Exact Sciences
  • Holds BS in Pharmacy and an MBA from the Kellogg School of Business at Northwestern University


Read Bio

Stephen Quake DPhil

  • Pioneer in liquid biopsy, single cell genomics, microfluidics
  • Co-President, Chan Zuckerberg Biohub
  • Professor, Bioengineering and applied physics Stanford University
  • Member of all three National Academies – Science, Engineering, and Medicine
  • Past Investigator, Howard Hughes Medical Institute

Read Bio

Alan Ashworth PhD FRS

  • Cancer biomarkers and therapeutics, DNA repair/synthetic lethality
  • President, Helen Diller Comprehensive Cancer Center
  • SVP for Cancer Services, UCSF Health
  • Professor, Hematology Oncology, UCSF

Read Bio

Mattias Westman

  • International finance and investments
  • Founding Partner, Prosperity Capital Management
  • Active global cross-border investor
  • Stockholm School of Economics

Read Bio

J. Craig Venter, PhD

  • Pioneer in sequencing Human Genome at Celera Genomics
  • Pioneer in genomic medicine, founder of Human Longevity Inc.
  • Founder of J. Craig Venter Institute

Read Bio

Felix Feng, MD

  • Radiation oncology leader in translational research
  • Significant expertise in identifying and treating aggressive prostate cancer
  • Director, Translational Genomics at University of Michigan, Ann Arbor

join us

great chemistry | big data | systems biology

We look for extraordinary lifelong learners with a passion and growth mindset for the above disciplines, and for combining biological ingenuity with AI and data analysis, to improve healthcare outcomes. Led by a team with decades of experience bringing products from concept to market, we have offices in the San Francisco Bay Area and San Diego.

Join us in addressing large healthcare needs through precision epigenomic medicine.

get in touch

SF Bay Area

155 Bovet Rd. Ste #400

San Mateo, CA 94402

San Diego

10578 Science Center Drive, Ste 210

San Diego, CA 92121